March 23, 2020 / 1:08 PM / in 17 days

BRIEF-Celsion’s GEN-1 Immunotherapy Receives Orphan Drug Designation From The European Medicines Agency

March 23 (Reuters) - Celsion Corp:

* CELSION’S GEN-1 IMMUNOTHERAPY RECEIVES ORPHAN DRUG DESIGNATION FROM THE EUROPEAN MEDICINES AGENCY

* CELSION CORP - GEN-1 PREVIOUSLY RECEIVED ORPHAN DESIGNATION FROM U.S. FOOD AND DRUG ADMINISTRATION

* CELSION CORP - GEN-1 IS CURRENTLY BEING EVALUATED IN A PHASE I/II CLINICAL TRIAL FOR TREATMENT OF NEWLY DIAGNOSED PATIENTS WITH STAGE III AND IV OVARIAN CANCER. Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below